DISEASE INDICATIONS: Psoriasis
MANUFACTURER: Almirall, S.A.
USAGE: Subcutaneous
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Ilumya (tildrakizumab) is a prescription medication used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is a monoclonal antibody that works by blocking the p19 subunit of interleukin-23 (IL-23), a cytokine that plays a key role in the development and progression of psoriasis.
